Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
$2.85
+6.7%
$1.69
$0.80
$3.42
$109.70M-0.891.13 million shs141,348 shs
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
$0.44
-2.1%
$0.39
$0.30
$10.62
$63.71M1.961.57 million shs673,519 shs
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
$2.14
-4.9%
$2.10
$1.55
$5.25
$15.82M0.2736,024 shs18,701 shs
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
$9.61
-3.7%
$11.32
$4.11
$28.68
$65.70M2.9142,125 shs35,772 shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
+6.74%-10.66%+57.46%+147.83%+18.75%
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
-2.07%-8.19%+30.27%-4.28%-92.58%
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
-5.93%-10.46%+4.90%-9.51%-59.62%
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
-3.71%-17.16%-30.56%+38.07%+43,558.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
1.6042 of 5 stars
3.33.00.00.00.61.70.0
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
4.1754 of 5 stars
3.33.00.04.71.81.71.3
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
1.7417 of 5 stars
2.05.00.00.00.01.70.6
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
3.1182 of 5 stars
3.55.00.00.00.01.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
2.50
Moderate Buy$5.5092.98% Upside
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
2.50
Moderate Buy$6.101,284.16% Upside
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
4.00
Strong Buy$5.00133.64% Upside
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
3.00
Buy$61.00534.76% Upside

Current Analyst Ratings Breakdown

Latest EDSA, ANEB, FBRX, and APLT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/23/2025
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
6/27/2025
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$5.00
6/24/2025
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$61.00
5/15/2025
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$6.00 ➝ $3.00
5/14/2025
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Perform ➝ Sector Perform$1.50 ➝ $1.50
(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
N/AN/AN/AN/A$0.15 per shareN/A
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
$460K135.64N/AN/A$0.49 per share0.90
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
N/AN/AN/AN/A$0.61 per shareN/A
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/AN/AN/AN/A$8.21 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
-$8.20M-$0.26N/AN/AN/A-90.11%-84.53%9/23/2025 (Estimated)
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
-$105.62M-$0.43N/AN/AN/AN/A-184.67%-84.02%8/6/2025 (Estimated)
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
-$6.17M-$1.59N/AN/AN/AN/A-187.01%-78.72%8/8/2025 (Estimated)
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
-$35.48M-$16.29N/AN/AN/AN/A-149.15%-114.25%8/13/2025 (Estimated)

Latest EDSA, ANEB, FBRX, and APLT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
-$1.21N/AN/AN/AN/AN/A
8/8/2025N/A
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
-$0.23N/AN/AN/AN/AN/A
8/6/2025Q2 2025
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
-$0.17N/AN/AN/A$0.42 millionN/A
5/15/2025Q1 2025
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
-$0.89-$1.37-$0.48-$1.37N/AN/A
5/14/2025Q2 2025
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
-$0.30-$0.30N/A-$0.30N/AN/A
5/13/2025Q3 2025
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
-$0.05-$0.04+$0.01-$0.04N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
N/AN/AN/AN/AN/A
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
N/AN/AN/AN/AN/A
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
N/AN/AN/AN/AN/A
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
N/A
25.29
25.29
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
N/A
3.00
3.00
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
N/A
15.72
15.72
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/A
5.22
5.22

Institutional Ownership

CompanyInstitutional Ownership
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
28.40%
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
98.31%
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
5.50%
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
77.63%

Insider Ownership

CompanyInsider Ownership
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
80.60%
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
1.60%
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
22.60%
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
5.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
441.08 million7.97 millionNot Optionable
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
30141.58 million139.31 millionOptionable
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
207.03 million5.44 millionNot Optionable
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
56.58 million6.20 millionOptionable

Recent News About These Companies

Forte Biosciences Inc News (FBRX) - Investing.com
Forte Biosciences Announces Proposed Public Offering
TD Cowen Remains a Buy on Forte Biosciences (FBRX)
Forte Biosciences price target lowered to $61 from $64 at Chardan
Forte Biosciences (FBRX) Gets a Buy from TD Cowen

New MarketBeat Followers Over Time

Media Sentiment Over Time

Anebulo Pharmaceuticals stock logo

Anebulo Pharmaceuticals NASDAQ:ANEB

$2.85 +0.18 (+6.74%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$2.86 +0.00 (+0.18%)
As of 08/1/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

Applied Therapeutics stock logo

Applied Therapeutics NASDAQ:APLT

$0.44 -0.01 (-2.07%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$0.44 +0.00 (+0.52%)
As of 08/1/2025 07:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Edesa Biotech stock logo

Edesa Biotech NASDAQ:EDSA

$2.14 -0.11 (-4.89%)
Closing price 08/1/2025 03:55 PM Eastern
Extended Trading
$2.25 +0.11 (+5.33%)
As of 08/1/2025 04:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

Forte Biosciences stock logo

Forte Biosciences NASDAQ:FBRX

$9.61 -0.37 (-3.71%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$9.56 -0.04 (-0.47%)
As of 08/1/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.